Trial Profile
Clinical and Biological Effects of Anti-IgE (Omalizumab) in Patients With Bilateral Nasal Polyposis and Asthma.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Omalizumab (Primary)
- Indications Asthma; Nasal polyps; Rhinosinusitis
- Focus Biomarker; Therapeutic Use
- 06 Mar 2012 Results presented at the 68th Annual Meeting of the American Academy of Allergy, Asthma and Immunology.
- 15 Jul 2011 New trial record
- 01 Dec 2009 Primary endpoint of total nasal endoscopic polyp score has been met.